Tragen starts Phase II CLL immunotherapy trial

Tragen Pharmaceuticals (San Diego, Calif.) began a U.S. Phase II trial of its ISF 154 personalized immunotherapy in 40 patients with chronic lymphocytic leukemia (CLL). Twenty chemotherapy refractory ...